Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus

Type 2 diabetes mellitus (T2DM) and cardiovascular disease are closely interconnected. We sought to determine the cardioprotective action of finerenone according to prior treatment with newer antidiabetics and glycemic status. We searched PubMed and Cochrane Library from inception to October 1, 2021...

Descripción completa

Detalles Bibliográficos
Autores principales: Patoulias, Dimitrios, Papadopoulos, Christodoulos, Karagiannis, Asterios, Vassilikos, Vassilios, Doumas, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Endocrine Society 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901958/
https://www.ncbi.nlm.nih.gov/pubmed/35144333
http://dx.doi.org/10.3803/EnM.2021.1296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901958/
https://www.ncbi.nlm.nih.gov/pubmed/35144333
http://dx.doi.org/10.3803/EnM.2021.1296

Ejemplares similares